32923 A multicenter, double-blind, randomized, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of spesolimab in patients with moderate-to-severe palmoplantar pustulosis

Burden, A. David; Bissonnette, Robert; Navarini, Alexander; Murakami, Masamoto; Morita, Akimichi; Mozzicato, Susan; Ye, Binqi; Baehner, Frank; Terada, Tadashi

doi:10.1016/j.jaad.2022.06.558

Search citation statements

Order By: Relevance

Paper Sections

Select...

Efficacy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A larger phase IIb multicenter randomized double‐blind placebo‐controlled study was recently completed on 152 patients with palmoplantar pustulosis with varying doses of spesolimab. However, the primary endpoint was not met for PPP in that study 35 …”

Section: Efficacymentioning

confidence: 85%

Spesolimab: a comprehensive review on the anti‐IL‐36 receptor antibody in dermatology

Palaniappan,

Gopinath,

Murthy

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

Interleukin‐36 (IL‐36) cytokines contribute to the pathogenesis of various inflammatory skin conditions and are potential therapeutic targets. Spesolimab is a monoclonal antibody that inhibits IL‐36 signaling recently approved by the Food and Drug Administration for the management of generalized pustular psoriasis flares in adults. Clinical trials are evaluating the efficacy of this monoclonal antibody in a few other dermatological conditions. Here, this review comprehensively summarizes the safety and efficacy of spesolimab treatment in various dermatological conditions.

show abstract

Section: Efficacymentioning

confidence: 85%